Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

What this doesn’t do is create the stable regulatory environment which is needed for companies to invest the hundreds of millions of dollars it costs to show that other new vaccines worth. Stuff like the Epstein-Barr virus vaccine will likely never become available, and we’ll never know if it’s possible to prevent Parkinson’s with a vaccine.